You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. An Innovative Device Integrating Cryopreservation, Storage, and Artificial Insemination of Mouse Sperm

    SBC: PARATECHS CORP            Topic: 100

    DESCRIPTION provided by applicant ParaTechs Corporation aims to provide researchers with advanced technology and methods to simplify procedures for laboratory animal models While actively supporting efforts to `reduce replace and refineandapos animal use ParaTechs provides safe and efficient alternatives for surgical procedures We have already brought to market a nonsurgical embryo transfe ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction

    SBC: ENDOPROTECH, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant According to the CDC in ischemic heart disease is the leading cause of death worldwide and in the US approximately patients died of ischemic heart disease It is well established in clinical practice that recanalization of he infarct related artery IRA using percutaneous coronary intervention PCI enhances myocardial salvage and outcomes in pa ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Chemical enhancement of CRISPR/Cas9 mediated site-specific genome engineering

    SBC: NERX BIOSCIENCES, INC.            Topic: 200

    DESCRIPTION provided by applicant Chemical enhancement of CRISPR Cas mediated site specific genome engineering Abstract Programmable nucleases including Zinc Finger Nucleases TALENs meganucleases and the CRISPR Cas system allow for site specific genome engineering The ability to make targeted genetic modifications has opened up a wide variety of options for scientists in industry and aca ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Chikungunya Recombinant Subunit Vaccine

    SBC: HAWAII BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Chikungunya virus CHIKV is an alphavirus classified as a category C priority pathogen that causes fever rash and arthralgia in humans In the past decade CHIKV outbreaks have spread beyond the endemic regions of Africa and Asia first to the islands in the Indian Ocean and most recently to the Americas The World Health Organization has reported that as ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Developing novel RPPA for the detection of metastatic prostate cancer

    SBC: TYMORA ANALYTICAL OPERATIONS LLC            Topic: 102

    PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an Assay Platform for Measuring Endogenous Kinase Activity

    SBC: Kinasense LLC            Topic: 100

    DESCRIPTION provided by applicant Kinase inhibitors are an effective class of targeted therapy for oncology However heterogeneous patient response and acquired resistance continues to be a significant clinical and economic burden To overcome this problem drug developers are pursuing novel kinase inhibitors for existing kinase targets with new modes of inhibition and increased potency as wel ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government